From Research to Practice: The Role of Mirabegron in Managing Overactive Bladder
Abstract
Millions of people in the world suffer from Overactive bladder (OAB). It is characterized by urinary incontinence, increased frequency, and nocturia, which leads to a compromise in the quality of the patient’s life. Traditional treatments comprised of antimuscarinic agents have limitations due to the side effects and reduced long-term effectiveness which creates a demand for alternative therapies. Treatment strategy for overactive bladder (OAB) has changed from antimuscarinics to β3-adrenergic receptor agonists after the discovery of mirabegron in 2012. This review examines the effectiveness of mirabegron in OAB patients and its integration into clinical practice. New advances in disease management mostly depend on the appropriate use of clinical data in guidelines for clarity. This is evident in OAB management with Mirabegron. The landscape has changed, providing new options for healthcare professionals. This review discusses the latest data on mirabegron use, efficacy, safety, cost-effectiveness, and its potential use in combination therapies. In addition to its position in OAB management, the futuristic use of this β3-adrenergic receptor agonist will also be explored.
Keywords:
Overactive bladder (OAB), Mirabegron, antimuscarinic agentsDOI
https://doi.org/10.25004/IJPSDR.2025.170114References
Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol. 2018;11:117-125. Available from: doi: 10.1159/000447205
Lukacz ES, Emily M, Whitcomb M, Lawrence JM, Nager CW, Karl M, et al. Urinary frequency in community-dwelling women: what is normal? Am J Obstet Gynecol. 2009;200:552.e1-552.e7. Available from: doi: 10.1016/j.ajog.2008.11.006
Cheng Y, Chen T, Zheng G, Song Z, Zhang G, Rao X, et al. Prevalence and trends in overactive bladder among men in the United States, 2005–2020. Scientific Report. 2024;14:16284. Available from: doi: 10.1038/s41598-024-66758-8
Rashid S, Babur MN, Khan RR, Khalid MU, Mansha H, Riaz S. Prevalence and associated risk factors among patients with overactive bladder syndrome in Pakistan. Pak J Med Sci. 2021;37:1185-1189. Available from: doi.org/10.12669/pjms.37.4.4262
Kim SY, Bang W, Choi HG. Analysis of the prevalence of and factors associated with overactive bladder in adult Korean women. PLoS One. 2017;12: e0185592. Available from: doi: 10.1371/journal.pone.0185592
Qudah S, Abufaraj M, Farah R, Almazeedi A, Ababneh A, Alnabulsi M, et al. The prevalence of overactive bladder and its impact on the quality of life: A cross-sectional study. Arab J Urol. 2023;22:39-47. Available from: doi: 10.1080/2090598X.2023.2221403
Lee KS, Choo MS, Seo JT, Kim HG, Ng K, Lee KJ, et al. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). Health Qual Life Outcomes. 2015;13:89. Available from: doi: 10.1186/s12955-015-0274-9
Choi H, Bae JH. Overview of the epidemiology of lower urinary tract dysfunction in South Korea. Int Neurourol J 2016;20:91-100. Available from: doi: 10.5213/inj.1630502.251
Funada S, Luo Y, Uozumi R, Watanabe N, Goto T, Negoro H, et al. Multicomponent intervention for overactive bladder in women. JAMA Netw Open. 2024;7:e241784 Available from: doi: 10.1001/jamanetworkopen.2024.1784
Salvatore S, Espuna-Pons M, Tubaro A. Urinary urgency: A Symptom in need of a cure. Res Rep Urol. 2019;11:327-331. Available from: doi: 10.2147/RRU.S216757
Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042. Available from: doi: 10.1038/nrdp.2017.42
Cornu JN, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, Michel MC, et al. A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management—a Systematic Review and Meta-analysis. European Urology. 2012;62: 877–890. Available from: doi: 10.1016/j.eururo.2012.07.004
Tomaszewski J. Postmenopausal overactive bladder. Prz Menopauzalny. 2014;13:313-329. Available from: doi: 10.5114/pm.2014.47984
Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. Res Rep Urol. 2016;8:71-76. Available from: doi: 10.2147/RRU.S102441
Shawahna R, Hijaz H, Jallad K, Abushamma M, Sawafta M. Prevalence of overactive bladder symptoms and their impact on health-related quality of life of medical and dentistry students: a multicenter cross-sectional study. BMC Urol. 2021;21:142. Available from: doi: 10.1186/s12894-021-00909-1
Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol. 2011;2011:820816. Available from: doi: 10.1155/2011/820816
Welk B, McClure. The impact of anticholinergic use for overactive bladder on cognitive changes in adults with normal cognition, mild cognitive impairment, or dementia. Eur Urol Open Sci. 2022;46:22-29. Available from: doi: 10.1016/j.euros.2022.10.008
Funada S, Watanabe N, Goto T, Negoro H, Akamatsu S, Ueno K, et al. Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial. BMC Urology. 2020;20:129. Available from: doi: 10.1186/s12894-020-00697-0
Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation. 2012; 125:1157-1170. Available from: doi: 10.1161/CIRCULATIONAHA.111.039453
Araklitis G, Baines G, Silva AS, Robinson D, Cardozo L. Recent advances in managing overactive bladder. F1000Res 2020;9:F1000 Faculty Rev-1125. Available from: doi: 10.12688/f1000research.26607.1
Kuo HC. Individualizing medical treatment of overactive bladder. Tzu Chi Med J.2018;30:195–199. Available from: doi: 10.4103/tcmj.tcmj_83_18
Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1:189-199. Available from: PMID: 18360559
Ochoa DC, Bouchard B, Abrams P. A historical perspective on anticholinergics in overactive bladder (OAB) treatment: Foundations, current practices, and future prospect s. Continence. 2024;12:101707. Available from: doi.org/10.1016/j.cont.2024.101707
Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther 2018;189:130-148. Available from: doi: 10.1016/j.pharmthera.2018.04.010
Abrams P, Andersson KE, Buccafusco JJ, Chapple C, Groat WC, Fryer AD, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565-578. Available from: doi: 10.1038/sj.bjp.0706780
Kuei CH, Peng CH, Liao CH. Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist. Urological Science. 2015;26:17-23. Available from: doi.org/10.1016/j.urols.2014.12.007
Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7:204-216. Available from: doi: 10.1177/2042098616659412
Wani M, Sheikh MI, Bhat T, Bhat Z, Bhat A. Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review. Curr Urol 2021;15:153-160. Available from: doi: 10.1097/CU9.0000000000000037
O’Kane M, Robinson D, Cardozo L, Wagg A, Abrams P. Mirabegron in the management of overactive bladder syndrome. Int J Womens Health. 2022;14:1337-1350. Available from: doi: 10.2147/IJWH.S372597
Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A randomized, placebo-controlled study (MATCH). European Urology Focus. 2020;6:729-737. Available from: doi: 10.1016/j.euf.2019.10.019
Frankel J, Saskin D, Varano S, Kennelly MJ, Jankowich RA, Haag-Molkenteller C. An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder. Ther Clin Risk Manag. 2022;18:171-182. Available from: doi: 10.2147/TCRM.S310371
Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd Jr PN. Efficacy of Vibegron and Mirabegron for overactive bladder: A Systematic Literature Review and Indirect Treatment Comparison. Adv Ther. 2021;38:5452-5464. Available from: doi: 10.1007/s12325-021-01902-8
Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, Nazir J, Chapple C. Efficacy and tolerability of Mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: A systematic review and network metaanalysis. Eur Urol. 2018;4:324-333. Available from: doi: 10.1016/j.eururo.2018.03.020
Huang CK, Lin C, Lin AT. Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting. Sci Rep. 2020; 10:11355. Available from: doi: 10.1038/s41598-020-68170-4
Kim TH, Lee K. Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol. 2016;57:84-93. Available from: doi: 10.4111/icu.2016.57.2.84
Schonburg S, Murgas S, Fornara P, Michel MC. Associations between the patient perception of bladder condition score and overactive bladder syndrome symptoms at baseline and upon treatment. Neurourol Urodyn. 2022;41:1399-1405. Available from: doi: 10.1002/nau.24960
Smits E, Andreotti F, Houben E, Crijns H, Haas S, Spentzouris G, et al. Adherence and persistence with once-daily vs twice-daily direct oral anticoagulants among patients with atrial fibrillation: Real-world analyses from the Netherlands, Italy and Germany. Drugs Real World Outcomes. 2022;9:199-209. Available from: doi: 10.1007/s40801-021- 00289-w
Dehvari N, Silva Junior ED, Bengtsson T, Hutchinson DS. Mirabegron: potential off target effects and uses beyond the bladder. Br J Pharmacol. 2018;175:4072-4082. Available from: doi: 10.1111/bph.14121
Yamada S, Niiya R, Ito Y, Kato Y, Onoue S. Comparative characterization of b- adrenoceptors in the bladder, heart, and lungs of rats: Alterations in spontaneously hypertensive rats. Journal of Pharmacological Sciences. 2022;148:51-55. Available from: doi: 10.1016/j.jphs.2021.10.003
Igawa Y, Aizawa N, Michel MC. β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions? Br J Pharmacol. 2019;176:2525-2538. Available from: doi: 10.1111/bph.14658
Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther. 2017;11:463-467. Available from: doi: 10.2147/DDDT.S101630
Bamfo NO, Hosey-Cojocari C, Benet LZ, Remsberg CM. Examination of urinary excretion of unchanged drug in humans and preclinical animal models: Increasing the predictability of poor metabolism in humans. Pharm Res. 2021;38:1139-1156. Available from: doi: 10.1007/s11095-021-03076-y
Ritchey ME, Wang J, Young JC, Chandra R, Carrera A, Goti N, et al. CYP2D6 substrate dispensing among patients dispensed Mirabegron: An administrative claims analysis. Drugs Real World Outcomes. 2023;10:119-129. Available from: doi: 10.1007/s40801-022- 00339-x
Chen L, Zhou L, Huang J, Wang Y, Yang G, Tan Z, Wang Y, Zhou G, Liao J, Ouyang D. Single- and Multiple-Dose trials to determine the pharmacokinetics, safety, tolerability, and sex effect of oral ginsenoside compound K in healthy Chinese volunteers. Front Pharmacol. 2018;8:965. Available from: doi: 10.3389/fphar.2017.00965
Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013; 189:1388-1395. Available from: doi: 10.1016/j.juro.2012.10.017
Orri M, Lipset CH, Jacobs BP, Costello AJ, Cummings SR. Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemp Clin Trials. 2014;38(2):190-197. Available from: doi: 10.1016/j.cct.2014.04.009
Takahashi S, Mishima Y, Kuroishi K, Ukai M. Efficacy of mirabegron, a β3 – adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int J Urol. 2022;29:7-15. Available from: doi: 10.1111/iju.14700
White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens. 2018;12:768-778.e1. Available from: doi: 10.1016/j.jash.2018.08.001
Rahimi K, Bidel Z, Nazarzadeh M, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021; 397:1625–1636. Available from: Available from: doi: 10.1016/S0140-6736(21)00590-0
Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32:621-638. Available from: doi: 10.1185/03007995.2016
Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU Guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol 2024;212:11-20. Available from: doi: 10.1097/JU.0000000000003985
Turell W, Howson A, MacDiarmid SA, Rosenberg MT. Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management. Int J Clin Pract. 2020;74:e13604. Available from: doi: 10.1111/ijcp.13604
Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Factors associated with improvements in patient-reported outcomes during Mirabegron or antimuscarinic treatment of overactive bladder syndrome: A registry study (PERSPECTIVE). Adv Ther. 2019;36:1906-1921. Available from: doi: 10.1007/s12325-019-00994-7
Yi W, Yang Y, Yang J. Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100:e27469. Available from: doi: 10.1097/MD.0000000000027469
Lin CS, Khan H, Chang R, Liao W, Chen Y, Siao S, et al. A study on the impact of poor medication adherence on health status and medical expense for diabetes mellitus patients in Taiwan: A longitudinal panel data analysis. Medicine (Baltimore). 2020; 99:e20800. Available from: doi: 10.1097/MD.0000000000020800
Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13:425-434. Available from: doi: 10.1111/luts.12382
Andersson KE. On the Site and Mechanism of Act ion of β3-Adrenoceptor Agonists in the Bladder. Int Neurourol J. 2017;21:6-11. Available from: doi: 10.5213/inj.1734850.425
Kuo Y, Kuo H. Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients. Tzu Chi Medical Journal. 2023;35:62-68. Available from: doi: 10.4103/tcmj.tcmj_209_21
Parise H, Espinosa R, Dea K, Anaya P, Montoya G, Ng DB. Cost Effectiveness of Mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in Colombia. Pharmacoecon Open. 2020;4:79-90. Available from: doi: 10.1007/s41669-019-0149-9
Published
Abstract Display: 110 
PDF Downloads: 96 How to Cite
Issue
Section
Copyright (c) 2025 Arijit Ghosh
This work is licensed under a Creative Commons Attribution 4.0 International License.
